entity

RNA_binding

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about RNA_binding: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2Connections
5Hypotheses
6Analyses
0Outgoing
2Incoming
7Experiments
8Debates

No AI portrait yet

Outgoing (0)

TargetRelationTypeStr
No outgoing edges

Incoming (2)

SourceRelationTypeStr
arginine_methylationinhibitsmechanism0.80
TDP-43regulatesprotein0.60

Targeting Hypotheses (5)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
RNA-binding protein condensate maturation from reversible ph 0.626 neurodegeneration Causal Sequence of TDP-43 Nuclear Cleara
RNA-binding protein condensate maturation from reversible ph 0.626 neurodegeneration Biophysical Determinants Shifting FUS/TD
RNA-Binding Protein Sequestration and 3′UTR Dysregulation 0.625 - How does the intron-retained RNA isoform
RNA-binding proteins stabilize or gate the lncRNA-0021:mmu-m 0.497 molecular neurobiology How does lncRNA-0021 achieve sequence-sp
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding 0.465 neurodegeneration Protein aggregation cross-seeding across

Mentioning Analyses (6)

Scientific analyses that reference this entity

Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Ag

neurodegeneration | 2026-04-27 | 4 hypotheses Top: 0.676

Which specific factors in conditioned medium from healthy astrocytes rescue moto

neurodegeneration | 2026-04-25 | 7 hypotheses Top: 0.730

RNA binding protein dysregulation across ALS FTD AD

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.664

RNA binding protein dysregulation across ALS FTD and AD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.720

TDP-43 phase separation therapeutics for ALS-FTD

neurodegeneration | 2026-04-01 | 0 hypotheses

Experiments (7)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
TDP-43 mutant mouse model cGAS/STING pathway analysis validation amyotrophic lateral sclerosis 0.900 0.00 TDP-43 mutant mice proposed N/A
TDP-43 mitochondrial invasion and DNA release via mPTP exploratory amyotrophic lateral sclerosis 0.900 0.00 cultured cells proposed N/A
TDP-43 mitochondrial invasion and mtDNA release in iPSC motor neurons exploratory Amyotrophic Lateral Sclerosis 0.900 0.00 iPSC-derived motor neurons proposed N/A
cGAS/STING pathway validation in TDP-43 mutant mice validation Amyotrophic Lateral Sclerosis 0.850 0.00 TDP-43 mutant mice proposed N/A
cGAMP biomarker analysis in ALS patient spinal cord samples exploratory Amyotrophic Lateral Sclerosis 0.800 0.00 Human ALS patient spinal cord proposed N/A
TDP-43 pathology prevalence and distribution in AD cases exploratory Alzheimer's disease 0.800 0.00 human postmortem brain tissue proposed N/A
Cognitive impact of TDP-43 pathology in AD patients clinical Alzheimer's disease 0.700 0.00 human patients completed N/A

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
TDP-43 Pathology in Alzheimer's Disease. [PMID:34930382] Meneses A, Koga S, O'Leary J, Dickson DW Mol Neurodegener 2021 2
Protein transmission in neurodegenerative disease. [PMID:32203399] Peng C, Trojanowski JQ, Lee VM Nat Rev Neurol 2020 2
TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS [PMID:33031745] Yu CH, Davidson S, Harapas CR, Hilton JB Cell 2020 2
ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies. [PMID:41570741] Genin EC, Paquis-Flucklinger V Current opinion in neurobiolog 2026 0
Refolding-assisted purification of native full-length TDP-43 compatible with BSL [PMID:41692368] Dehury S, Tiwari S, Los Rios P Methods 2026 0
Small heat shock proteins HspB1 and HspB5 differentially alter the condensation [PMID:41854301] Walker TB, Trowbridge JW, McMahon S, Mar Protein Sci 2026 0
Structural and Mechanistic Heterogeneity of the Phase Separation and Aggregation [PMID:41871974] Doke AA, Kirmire MS, Jha A, Jha SK ACS Chem Neurosci 2026 0
The Genetics of TDP-43 Type C Neurodegeneration: A Whole-Genome Sequencing Study [PMID:41883703] Nassan M, Ayala I, Sloan J, Bonfitto A, Neurology. Genetics 2026 0
Circular RNAs from the MAPT and TARDBP genes: Novel players in neurodegeneration [PMID:40633584] ["Bagheri N", "Margvelani G", "Chiang T" Neurochemistry international 2025 0
Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-4 [PMID:40252666] Balendra R, Sreedharan J, Hallegger M, L The Lancet. Neurology 2025 0
TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP- [PMID:34916658] Xie M, Liu YU, Zhao S, Zhang L, Bosco DB Nature neuroscience 2022 0
Magnetic control of tokamak plasmas through deep reinforcement learning. [PMID:35173339] Degrave J, Felici F, Buchli J, Neunert M Nature 2022 0
FUS and TDP-43 Phases in Health and Disease. [PMID:33446423] ["Portz Bede", "Lee Bo Lim", "Shorter Ja Trends in biochemical sciences 2021 0
FUS and TDP-43 Phases in Health and Disease. [PMID:33446423] ["Portz Bede", "Lee Bo Lim", "Shorter Ja Trends in biochemical sciences 2021 0
Cardiomyocyte-derived calcitonin regulates atrial fibrosis and AF. [PMID:33199879] Fernández-Ruiz I Nature reviews. Cardiology 2021 0
SMS2 deficiency impairs PKCδ-regulated B cell tolerance in the germinal center. [PMID:34469734] Ou P, Stanek A, Huan Z, Roman CAJ, Huan Cell reports 2021 0
TDP-43 condensation properties specify its RNA-binding and regulatory repertoire [PMID:34380047] Hallegger M, Chakrabarti AM, Lee FCY, Le Cell 2021 0
TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS [PMID:33031745] Yu CH, Davidson S, Harapas CR, Hilton JB Cell 2020 0
Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-de [PMID:30643298] Melamed Ze'ev; López-Erauskin Jone; Nature neuroscience 2019 0
Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-de [PMID:30643298] Melamed Z, López-Erauskin J, Baughn MW, Nature neuroscience 2019 0

Debates (8)

Multi-agent debates referencing this entity

What are the biophysical determinants — RNA binding stoichiometry, post-translat

active · Rounds: 4 · Score: 0.67 · 2026-04-28

Hypothesis debate: Stathmin-2 Splice Switching to Prevent Axonal Degeneration Ac

closed · Rounds: 4 · Score: 0.49 · 2026-04-27

Which specific factors in conditioned medium from healthy astrocytes rescue moto

closed · Rounds: 4 · Score: 0.65 · 2026-04-25

RNA binding protein dysregulation across ALS FTD AD

closed · Rounds: 4 · Score: 0.50 · 2026-04-13

RNA binding protein dysregulation across ALS FTD and AD

closed · Rounds: 4 · Score: 0.72 · 2026-04-12

RNA binding protein dysregulation across ALS FTD and AD

closed · Rounds: 4 · Score: 0.88 · 2026-04-06

What are the mechanisms underlying tdp-43 phase separation therapeutics for als-

closed · Rounds: 4 · Score: 0.95 · 2026-04-01

What are the mechanisms underlying protein aggregation cross-seeding across neur

closed · Rounds: 4 · Score: 0.95 · 2026-04-01

Related Research

Hypotheses and analyses mentioning RNA_binding in their description or question text

No additional research found